Literature DB >> 2219572

Natural history of low-stage prostatic cancer and the impact of early detection.

W F Whitmore1.   

Abstract

An expanding and increasingly older population, a rising incidence of prostate cancer, and uncertainties regarding treatment effectiveness have made this disease a target of special concern. The natural history of the cancer must be a consequence of host-tumor interactions, but little is known for sure about this subject. The growth rate of the tumor is determined by many factors, including genetic instability. At present, tumor grade, volume, and ploidy are the most useful techniques for judging the growth rate and metastatic potential. Stage A1 tumors generally are indolent, whereas stage A2 tumors are more aggressive. The natural history of stage B lesions is not well documented. The author asks two questions (Is cure necessary in those in whom it may be possible? Is cure possible in those in whom it may be necessary?) and reviews the problems inherent in screening for prostate cancer at this time.

Entities:  

Mesh:

Year:  1990        PMID: 2219572

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  8 in total

1.  Focal therapy for localized prostate cancer -choosing the middle ground.

Authors:  Uri Lindner; John Trachtenberg
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

Review 2.  Prostate cancer, screening, and prostate-specific antigen: promise or peril?

Authors:  J D Voss
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

3.  Screening for prostatic cancer.

Authors:  A K Nigam
Journal:  BMJ       Date:  1993-03-27

4.  Should patients with a pre-operative prostate-specific antigen greater than 15 ng/ml be offered radical prostatectomy?

Authors:  M F O'Brien; S S Connolly; D G Kelly; A O'Brien; D M Quinlan; D W Mulvin
Journal:  Ir J Med Sci       Date:  2004 Jan-Mar       Impact factor: 1.568

5.  Diagnosis, prognosis and management of incidentally found prostate cancer.

Authors:  P J Davidson
Journal:  Urol Res       Date:  1993-01

6.  Screening for prostate cancer. How can patients give informed consent?

Authors:  K G Marshall
Journal:  Can Fam Physician       Date:  1993-11       Impact factor: 3.275

Review 7.  Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention.

Authors:  K S Chaudhary; P D Abel; E N Lalani
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

8.  Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.

Authors:  A S Adamson; P Luckert; M Pollard; M E Snell; M Amirkhosravi; J L Francis
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.